Home › Forums › Main Forum › Media & News › Investors Business Daily: How AbbVie Could Hammer Gilead …
- This topic has 7 replies, 5 voices, and was last updated 7 years, 5 months ago by Greedfighter.
-
AuthorPosts
-
21 July 2017 at 8:55 am #26619
Article about AbbVie’s potential to take market share from Gilead.
http://www.investors.com/news/technology/how-abbvie-could-hammer-gileads-hepatitis-c-franchise/
22 July 2017 at 12:27 am #26622So, bonus points for Abbvie investors, then?
Still, its a pity that curing the world of a major disease is still something the business world fails to understand…
—-
First there was prohibition and gangsters like Al Capone. Then the wise guys moved to Las Vegas and organised crime became legal.
Now there is Big Pharma, and organised crime is even more legal and widespread.
Bastard gangsters, all of them!
Diagnosed Jan 2015: GT3, A0+F0/F1. Fatigue + Brain-Fog.
Started Sof+Dac from fixHepC 10-Nov-2015. NO sides.
Pre-Tx: AST 82, ALT 133, Viral Load 1 900 000.
Week4: AST 47, ALT 58. VL < 15 (unquantifiable). Week12 (EOT): AST 30, ALT 26, VL UND Week16 (EOT+4): AST 32, ALT 28, GGT 24, VL UND Week28 (EOT+16): AST 26, ALT 22, GGT 24, VL UND Ever grateful to Dr James. Relapsed somewhere after all that... Bummer! Jan 2018: VL 63 000 (still GT3).22 July 2017 at 2:44 am #26623here is a few that have been riling me past day or 2- in this one, Forbes, author defends Gilead pricing as reasonable- the comments are infuriating- our lives are treated like shoe sizes. I made a comment, it survived 2 hours, but it must have hurt the rich boys feelings as it is gone now. I’m trying another thing- replying to the existing ones, lets see. I am going to keep going back. https://www.forbes.com/sites/johnlamattina/2017/07/19/when-it-comes-to-abusive-drug-pricing-dont-confuse-shkreli-with-hep-c-drugs/#30fdbe1aaf68
And this- lawyers fees- could cure whole countries for this one case between 2 disgraceful corporations:
https://l.facebook.com/l.php?u=http%3A%2F%2Fwww.americanlawyer.com%2Fid%3D1202793318711%2FFish-amp-Richardson-Set-to-Receive-125M-Fee-Award-in-GileadMerck-Infringement-Battle%3Fmcode%3D1202617075486%26curindex%3D0%26slreturn%3D20170619054405&h=ATMsP51CbDXIpk33JRVQ34JJl_RoxioRId5vWjQVdEIf3tNnTLCicJCjsZNs8o6GqCfgph7tbVTeCeDyYmJNmYHmMAENzxExY7eLs4X9tJ2XfbSPFpCi_z4w9e8kXQWB7Mps_ukCkpW2gONbi9hTa4wxgoyfBw&s=1&enc=AZNiIZFbdm9BBZCoisYA4K890b-vDKSW5NKmIub_R5_C3dmAGNGRzspp0Tgbiu0xU9AYC1OX_UGlPmWP23UEwrDgpFd2BGzUN13lConDvOr2Vw
Genotype 3 30 years, 2x treatment interferon/ribavirin non responder. Cirrhosis 17 years. Fibroscan, decompensating, 40 down to 22 by 29/3/16- now down to 6.5, normal, no cirrhosis. Started Buyers Club Sof/Dac 14 Nov 15. SVR 12 29/0716
22 July 2017 at 9:00 am #26625Hi Hazel & klhilde,
my view is that both articles are in fact a red herring. (https://en.wikipedia.org/wiki/Red_herring), as it tries to sidetrack the reader by raising an irrelevant (or less relevant) topic (e.g. there is competition between Big Pharma companies or HCV drugs are prices in US similarly as in the rest of the world …. ) and afterwards claiming that the original issue (people die because they cannot afford the high prices) has been settled.
@Hazel: I do agree: the article from Forbes is rubbish.
Firstly, the title which is attracting the attention, is not sustained by the content of the article. The conclusions at the end of the article does not sustain why in fact someone should not confuse Shrekli with Hep C drugs when it comes to prices. One might guess why, but the author should have had explained better his view.Secondly, this LaMattina guy is attacking Froma Harrop saying that her op-ed is fraught with inaccuracies, yet he misses the fact that Froma Harrop mentioned 1 valid argument which was sustained by the content of her article:
– Clearly, the industry needs a new business model in which costs of development are fairly shared. The same goes for breaks on price.This is a strong conclusion of Froma Harrop that LaMattina is not attacking.
What he does instead is to put in some context (aka the red herring) to distract the attention and induce an idea about how “good” Gilead is.And thirdly, the conclusions he presents at the end of his article are missing the issue raised by Froma Harrop (that the industry needs a new business model… ) and he formulates his attack on her on the generally valid statement which is not targeting the patent holder’s of Hep C drugs in particular, rather the inflated prices in US for the healthcare:
Froma Harop: “and
-The real problem in American health care is not that we can’t afford what we need. Other countries with far less resources provide as good or better health care than we do. The problem is that, by international standards, we pay inflated prices for just about everything.” (yeah, I could accept this argument without too much debate)LaMattina: “the new Hep c drugs… are priced, for the vast majority of Americans, similarly to the rest of the world” (and does this “red herring” means that the rest of the world is paying a fair price??? )
So LaMattina clearly missed the point that Froma Harop raised and his attack on her shows just how much unprepared he wrote the article.
I just threw the article from LaMattina into the latrine…
Cheers,
RHF
In fiecare an HCV ucide peste 500000 oameni.Medicamentele generice pentru hepatita C functioneaza. Nu deveni statistica! Cauta pe Google “medicamente generice pentru hepatita C”.
HCV kills more than 500000 people every year. HCV generic drugs work. Don’t become a statistic.
By sharing this Youtube video you might save someone’s life!
My TX: HEPCVIR-L[generic Harvoni]-India
SVR52 achieved23 July 2017 at 2:09 am #26626The real problem is that greed has consumed humanity, especially the wealthy and disloyal corporations only interested in profits. There is no mission associated with health care. They may as well be producing pesticides. It’s only about profitability. It turns out human beings are no better than roaches in terms of compassion.
Thank God for Fix Hep C. On a side note, a Google search for generic hep c medication now has Fix Hep C first after paid sponsors. So there are apparently some good people working at Google. So those interested in searching for a cure can easily find this opportunity. For those who don’t search, tragically they are doomed.
23 July 2017 at 3:59 am #26627Great comment on Forbes Kevin! and Greedfighter- perfect “they may as well be making pesticides”. I would like to use that line.
Genotype 3 30 years, 2x treatment interferon/ribavirin non responder. Cirrhosis 17 years. Fibroscan, decompensating, 40 down to 22 by 29/3/16- now down to 6.5, normal, no cirrhosis. Started Buyers Club Sof/Dac 14 Nov 15. SVR 12 29/0716
23 July 2017 at 5:11 am #26628Thanks Hazel.
Little by little I’m getting better at writing my comments such that they get past moderation. Notice my strategically placed appeal to authority.
And the mention of forums and generics and medical tourism seems quite innocently placed, does it not?
But anyone motivated to click on the story would likely be bright enough to hit Google after reading my comment … or at least I hope so.
______________________And while I agree with what everyone is saying about the companies’ greed, we still have to be realistic about this.
We need a change to patent law … That’s not happening in the foreseeable future.
We need to get the word out about generics … Try as we may, our penetration is comparatively small.So while we’re figuring out how to make a bigger impact, all we have for the majority of people is market pressures. And with Gilead, the attempt to protect/defend market share is likely the only thing that will bring any noticable results.
23 July 2017 at 5:29 am #26629Hi Hazel,
Please feel free to use any of my comments as your own.
-
AuthorPosts
- You must be logged in to reply to this topic.